In what feels like an eternity in biotechnology terms, broader baskets of the industry’s stocks haven’t outperformed the S&P 500 Health Care Index annually since 2020. That streak could end this year, but biotech stocks and ETFs still aren’t on fire. This concerns some market observers at a time when growth stocks are soaring. That [...] The post Biotech Still Has Disruptive Capabilities appeared first on ETF Trends .